Integrated Pharmaceuticals, Inc. Announces Marketing Agreement with M2 Formulex Inc. (Canada)

FITCHBURG, Mass., June 2 /PRNewswire-FirstCall/ --

Integrated Pharmaceuticals, Inc. (IntePharm)(OTC: INTP), announced today that it has signed an exclusive product marketing agreement with M2 Formulex Inc. (M2), a Toronto, Canada based marketing and business development services firm, for its specialty beverage products. IntePharm and M2 expect that sales of these products will reach $250,000 (US) per month in the fourth quarter of 2005, and could exceed $1 million (US) per month during calendar year 2006.

IntePharm's specialty beverage products uniquely deliver nutrients such as calcium in a manner that does not noticeably affect the taste or flavor of the beverage. To the best of IntePharm's knowledge, no other manufacturer has a similar product on the market. The Company's patent-pending technology can be applied to several other applications that will allow beverage companies to deliver healthy products to consumers at an affordable price. IntePharm said that M2 signed this exclusive marketing agreement after consumers tested the samples of IntePharm's specialty beverage products and completed a preliminary field application trial. IntePharm is exploring other potential licensing opportunities for its specialty beverage products, and is currently finalizing arrangements for the packaging of these products for another customer.

"We are excited that our strong intellectual property portfolio has led to a marketing agreement with M2 Formulex Inc." said Dr. Chinmay Chatterjee, CEO of Integrated Pharmaceuticals. Dr. Chatterjee said further, "M2 has a proven track record of successful introductions of similar products in US and Canadian markets." Michael Chernyak, President of M2 Formulex Inc. said, "M2 has conducted an evaluation of IntePharm's proprietary beverage technology and, based on this evaluation, we are confident that it offers consumers an important benefit in a highly convenient format. We are excited to introduce IntePharm's innovative technology to well-positioned beverage marketers servicing retail food and drug chains, mass merchandisers, foodservice chains,
nutraceutical companies and multi-level marketing firms in both the US and Canada."

About IntePharm

IntePharm is an emerging producer of pharmaceuticals, specialty compounds and chemicals for the pharmaceutical, nutraceutical and food industries. In
addition to making products, IntePharm discovers and develops more efficient and cost-effective manufacturing processes. These processes are developed using a comprehensive technology platform that combines metabolic engineering, cellular genetics, advanced bioprocess engineering, and computer simulation science. The company owns several other pending patents for new products and technologies for immediate commercialization in food and nutritional products market.

About M2 Formulex, Inc.

M2 Formulex Inc. markets unique and innovative technologies and concepts to the food and beverage, nutraceutical, health and personal care industries. Headquartered in Toronto, Ontario, Canada with affiliate offices in Glendale, New York and Minneapolis, Minnesota, M2 works closely with owners of cutting-edge food ingredients, packaging, nutraceutical delivery systems, and health and personal care technologies. M2's principals combine in excess of thirty years of greater food and beverage industry experience, bringing a proven track record of delivering real, measurable results in today's complex marketing, selling and operational processes.

For further information please contact Dr. Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. (IntePharm), at (978) 696-0020, or visit http://www.intepharm.com or Michael Chernyak, at (905)-760-1176, Ext. 222 or visit http://www.m2formulex.com.

Forward-Looking Statements

Certain statements contained in this press release that are not historical facts constitute "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in general, predict, indicate or imply future results, performance or achievements and generally use words so indicative. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company and its business to be materially different from that expressed or implied by such forward-looking statements. Included in those factors are the following: our dependence on a limited number of potential customers; limited managerial experience of our executives; possible needs for additional capital; possible delays in product development and delivery schedules; the complexity of marketing, promoting, packaging and distributing new consumer products; deferred or lost sales because of the complex sales process prevalent in the industries that we seek to serve; increased competitive pressure; and rapid technological changes. Forward-looking statements by their very nature are uncertain. There can be no guarantee that any forward-looking statement will be fulfilled. The Company assumes no obligation to update forward-looking statements to reflect actual results or changes in or additions to the factors
affecting such forward-looking statements.

SOURCE Integrated Pharmaceuticals, Inc.
Web Site: http://www.intepharm.com http://www.m2formulex.com

SOURCE Integrated Pharmaceuticals, Inc. Web Site: http://www.intepharm.com

Copyright © 1996-2004 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.